Summary
The provided AI claims are primarily about FDA approval year and patent/protection/market effects, but the supplied FDA label excerpt contains only limited boxed-warning/contraindications/overdose/patient counseling content and does not support or address patent or approval-history claims. Therefore label alignment cannot be reliably assessed, and most claims are unsupported by the supplied prescribing information.
Category Scores
Accurate Statements
None of the listed AI claims are directly supported by the provided FDA label excerpt.
The excerpt provided includes: boxed warnings (premature discontinuation; spinal/epidural hematoma), contraindications (active pathological bleeding; severe hypersensitivity), and some overdose/patient counseling information. It does not contain information about FDA approval date, patent filing/grant/expiration, exclusivity termination, generic availability timing, or market/payer/patient access effects.
Unsupported Statements
Eliquis (apixaban) was first approved by the US FDA in 2012.
Not supported by the supplied prescribing information excerpt.
The Eliquis patent was filed in 2007.
Not supported by the supplied prescribing information excerpt.
The Eliquis patent was granted in 2011.
Not supported by the supplied prescribing information excerpt.
Eliquis patent protection is set to expire on August 5, 2028.
Not supported by the supplied prescribing information excerpt.
When the Eliquis patent expires, the patent holder's exclusive rights to make, use, and sell Eliquis end.
Not supported by the supplied prescribing information excerpt.
After the Eliquis patent expires, generic versions of Eliquis can be developed and marketed by other companies.
Not supported by the supplied prescribing information excerpt.
After Eliquis patent expiration, generic versions of Eliquis will become available, leading to increased competition and lower prices.
Not supported by the supplied prescribing information excerpt.
After Eliquis patent expiration, patients may have better access to the medication due to availability of generic versions.
Not supported by the supplied prescribing information excerpt.
Eliquis patent expiration may impact the revenue of Pfizer and Bristol-Myers Squibb because they will no longer have exclusive rights to sell Eliquis.
Not supported by the supplied prescribing information excerpt.
Generic versions of Eliquis are subject to rigorous testing and approval by regulatory agencies for quality and efficacy.
Not supported by the supplied prescribing information excerpt.
Contradictions
Important Omissions
The AI response makes multiple non-label claims (approval history and patent/exclusivity/generic-market effects) while providing no label-grounded statements regarding the drug’s FDA-approved indications, dosing/administration, contraindications, boxed warnings, warnings/precautions, drug interactions, monitoring, adverse reactions, or storage/handling.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims are about patent/market/access and do not directly provide dosing or clinical instructions. However, they are not supported by the supplied FDA label excerpt, so their regulatory accuracy is questionable.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are not present in (or supported by) the supplied FDA-approved prescribing information excerpt.
Suggested Improvement
Limit statements to content explicitly supported by the provided label excerpt (e.g., boxed warnings about premature discontinuation and neuraxial anesthesia/puncture risk; contraindications; overdose management notes; patient counseling items). Do not include FDA approval-year, patent filing/grant/expiration, or market/exclusivity effects unless those facts are included in the supplied prescribing information.